Evolving Evidence of the Efficacy and Safety of <i>nab</i>-Paclitaxel in the Treatment of Cancers with Squamous Histologies

Loong, Herbert H.; Chan, Alvita C.Y.; Wong, Ashley C.Y.

doi:10.7150/jca.12986

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2016; 7(3):268-275. doi:10.7150/jca.12986 This issue Cite

Review

Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies

Herbert H. Loong^1,2✉, Alvita C.Y. Chan², Ashley C.Y. Wong²

1. Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR
2. Department of Clinical Oncology, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR

Citation:

Loong HH, Chan ACY, Wong ACY. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. J Cancer 2016; 7(3):268-275. doi:10.7150/jca.12986. https://www.jcancer.org/v07p0268.htm

Other styles

Abstract

Taxanes, such as paclitaxel and docetaxel, are well-established cytotoxic chemotherapeutics used in the treatment of a variety of cancers, including those of squamous histology. In their formulation, both agents require solvents, which have been associated with hypersensitivity reactions, peripheral neuropathy, hepatic toxicities, and impaired drug delivery. nab-Paclitaxel is a novel, albumin-bound form of paclitaxel with improved tolerability, bioavailability, and efficacy compared with solvent-based paclitaxel. Currently, nab-paclitaxel is approved for the treatment of metastatic breast cancer, locally advanced/metastatic non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer. Clinical studies suggest that nab-paclitaxel may be particularly effective in cancers with squamous histology, including NSCLC. This article reviews the emerging evidence supporting nab-paclitaxel as an effective agent in the treatment of malignancies of squamous histology.

Keywords: nab-paclitaxel, squamous cell carcinoma, non-small cell lung cancer (NSCLC), head/neck cancer, nasopharyngeal carcinoma, esophageal cancer

Citation styles

APA

Loong, H.H., Chan, A.C.Y., Wong, A.C.Y. (2016). Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. Journal of Cancer, 7(3), 268-275. https://doi.org/10.7150/jca.12986.

ACS

Loong, H.H.; Chan, A.C.Y.; Wong, A.C.Y. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. J. Cancer 2016, 7 (3), 268-275. DOI: 10.7150/jca.12986.

NLM

CSE

Loong HH, Chan ACY, Wong ACY. 2016. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies. J Cancer. 7(3):268-275.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.